Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | ESRRB | O95718 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESRRG | P62508 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603274 | 0.93 | ESRRG (0.55) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL2603275 | 0.87 | DRD2 (0.53) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL2603286 | 0.83 | KCNH2 (0.47) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL23993613 | 0.83 | KCNH2 (0.47) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL2603312 | 0.83 | KCNH2 (0.61) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL7331632 | 0.83 | ESRRB (0.46) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL2603330 | 0.83 | DRD2 (0.49) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL13015008 | 0.78 | QDPR (0.49) | KCNH2ESR1ATM | |
| SCHEMBL12026437 | 0.78 | KCNH2 (0.50) | KCNH2ESRRBESR1ESRRGHRH3 | |
| SCHEMBL1475617 | 0.76 | ESRRG (0.55) | KCNH2ESRRBESR1ESRRGHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | KCNH2 4329/4885ESRRB 119/4885ESR1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.